Circulation:内皮细胞Foxp1通过TGF-β1-内皮素-1通路调控病理性心室重

2019-09-05 MedSci MedSci原创

病理性心肌纤维化和心肌肥厚,是左心室重构的共同特征,常进展成心力衰竭(心衰)。内皮细胞上的叉头框转录因子P1 (Foxp1)在心脏发育过程中起着重要作用。但EC-Foxp1对病理性心室重构的作用基本尚未明确。现研究人员对EC-Foxp1在病理性心脏重构中的作用及其机制进行研究。通过建立EC特异性Foxp1功能丧失或恢复的小鼠模型以及血管紧张素II灌注或主动脉缩窄术处理的小鼠模型来研究心室重构的机制

病理性心肌纤维化和心肌肥厚,是左心室重构的共同特征,常进展成心力衰竭(心衰)。内皮细胞上的叉头框转录因子P1 (Foxp1)在心脏发育过程中起着重要作用。但EC-Foxp1对病理性心室重构的作用基本尚未明确。现研究人员对EC-Foxp1在病理性心脏重构中的作用及其机制进行研究。

通过建立EC特异性Foxp1功能丧失或恢复的小鼠模型以及血管紧张素II灌注或主动脉缩窄术处理的小鼠模型来研究心室重构的机制。

血管紧张素II诱导的心室重构过程中,Foxp1的表达明显下调。EC-Foxp1缺失可导致严重的心室重构,包括心肌纤维化、成肌成纤维细胞形成和细胞外基质蛋白生成增多,以及失代偿性心肌肥厚,并进一步加剧血管紧张素II灌注或主动脉缩窄术后的心功能障碍。相反,EC-Foxp1功能增强则可预防病理性心室重构、改善心功能障碍。TGF-β1信号是Foxp1的直接靶基因,敲除EC-Foxp1可上调TGF-β1信号,通过纤维母细胞增殖促进成纤维细胞增多,最终导致严重的心脏纤维化。此外,敲除EC-Foxp1还可增强TGF-β1促进的内皮素-1的表达,内皮素-1可显著增加心肌细胞的大小和重激活心脏胎儿基因,导致病理性心脏肥大。相应的,敲除EC-Foxp1所介导的纤维化和心肌肥大以及心功能障碍等表现可通过阻断TGF-β1信号来恢复正常。

EC-Foxp1通过TGF-β1-内皮素-1通路调控病理性心脏纤维化和肥大,导致心脏功能障碍。因此,靶向EC-Foxp1-TGF-β1-内皮素-1通路或可为心力衰竭的治疗提供一个新的方案。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035894, encodeId=5632203589466, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Feb 28 14:13:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957270, encodeId=3ea1195e2705c, content=<a href='/topic/show?id=f92e3045357' target=_blank style='color:#2F92EE;'>#内皮素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30453, encryptionId=f92e3045357, topicName=内皮素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue May 26 08:13:00 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011140, encodeId=e1e120111405a, content=<a href='/topic/show?id=0a351e34776' target=_blank style='color:#2F92EE;'>#TGF-β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17347, encryptionId=0a351e34776, topicName=TGF-β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Aug 12 05:13:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441379, encodeId=b9a414413e962, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Sat Sep 07 14:13:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
    2020-02-28 changhe713
  2. [GetPortalCommentsPageByObjectIdResponse(id=2035894, encodeId=5632203589466, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Feb 28 14:13:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957270, encodeId=3ea1195e2705c, content=<a href='/topic/show?id=f92e3045357' target=_blank style='color:#2F92EE;'>#内皮素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30453, encryptionId=f92e3045357, topicName=内皮素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue May 26 08:13:00 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011140, encodeId=e1e120111405a, content=<a href='/topic/show?id=0a351e34776' target=_blank style='color:#2F92EE;'>#TGF-β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17347, encryptionId=0a351e34776, topicName=TGF-β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Aug 12 05:13:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441379, encodeId=b9a414413e962, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Sat Sep 07 14:13:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2035894, encodeId=5632203589466, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Feb 28 14:13:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957270, encodeId=3ea1195e2705c, content=<a href='/topic/show?id=f92e3045357' target=_blank style='color:#2F92EE;'>#内皮素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30453, encryptionId=f92e3045357, topicName=内皮素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue May 26 08:13:00 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011140, encodeId=e1e120111405a, content=<a href='/topic/show?id=0a351e34776' target=_blank style='color:#2F92EE;'>#TGF-β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17347, encryptionId=0a351e34776, topicName=TGF-β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Aug 12 05:13:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441379, encodeId=b9a414413e962, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Sat Sep 07 14:13:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2035894, encodeId=5632203589466, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Feb 28 14:13:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957270, encodeId=3ea1195e2705c, content=<a href='/topic/show?id=f92e3045357' target=_blank style='color:#2F92EE;'>#内皮素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30453, encryptionId=f92e3045357, topicName=内皮素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue May 26 08:13:00 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011140, encodeId=e1e120111405a, content=<a href='/topic/show?id=0a351e34776' target=_blank style='color:#2F92EE;'>#TGF-β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17347, encryptionId=0a351e34776, topicName=TGF-β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Aug 12 05:13:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441379, encodeId=b9a414413e962, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Sat Sep 07 14:13:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]

相关资讯

Blood:FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。

滤泡性淋巴瘤(FL)是一种在临床上和分子上都具有高度异质性的疾病,目前预测主要是依赖于临床检验。研究人员近期发现7个基因(包括EZH2和MEF2B)突变状态的综合,会提高风险分层。研究人员收集基因表达数据来揭示在EZH2和MEF2B突变的病例中的差异性表达的基因。经过筛查,研究人员集中于FOXP1基因,运用免疫组化(IHC)检测763份组织样本FOXP1蛋白的表达量。为了结果的相关性,纳入了一个包

Cereb Cortex:自闭症相关的无义Foxp1突变体诱导自噬并延迟皮层神经元的径向迁移

温州医科大学眼科学与眼科医院的Li X等人在Cereb Cortex发表了一项重要研究,他们通过构建了Foxp1(R521X)的人源突变体的小鼠,研究发现发育中的神经元细胞通过自噬作用但不通过NMD作用作为抵抗无义突变体聚集的保护机制,导致皮质发育受损。

Blood:MiR-150下调通过上调FOXP1促进滤泡性淋巴瘤向高级别淋巴瘤转化

中心点:转化FL可下调miR-150,导致FOXP1蛋白上调。上调MYC蛋白可抑制miR-150在转化FL中的表达。摘要:滤泡性淋巴瘤(FL)是一种常见的惰性B细胞恶性肿瘤,临床病程多变,并且其组织学病理可转化成高级别的淋巴瘤,即典型弥漫性大B细胞淋巴瘤(DLBCL)。近期,有研究表明MYC的遗传变异或过表达与FL转化(tFL)相关。但是,FL转化的潜在分子机制尚未完全明了。Katerina Mu